Vir is holding off on advancing the combination therapy to Phase III trials until it secures a development partner.

The findings, highlighted across five posters, underscored significant advancements in achieving functional cures for chronic ...

Vir Biotechnology’s sidelined hepatitis B candidate, designed to serve as a “functional cure,” has failed to achieve the ...

Vir Bio (VIR) reveals 24-week post-end-of-treatment data from a mid-stage trial for its Hep B therapy developed with Xencor ...

The Knox County Health Department shared in a press release that each May, the United States observes Hepatitis Awareness Month to bring attention to viral hepatitis and ...

Vir Biotechnology, Inc. progresses HDV treatment with promising ECLIPSE program results. Click here to find out why VIR stock ...

A common medication used to treat HIV and hepatitis B may offer unexpected protection against Alzheimer's disease.

A new report released today by the World Hepatitis Alliance (WHA) reveals widespread knowledge gaps, inequities in access, ...

Functional cure of chronic hepatitis B (CHB) remains a major clinical challenge. Current therapies—including nucleos(t)ide ...

However, there are currently no drugs specifically designed to treat liver fibrosis. Our Phase 2 trial of hydronidone for the treatment of chronic hepatitis B (CHB)-associated liver fibrosis showed ...

This treatment centre will focus solely on patients who have come in contact with the justice system. 2:06 B.C. provides involuntary treatment guidance to health-care professionals “This is the ...